Warren Buffett and Stephen Curry Charity Dinner Auction Raises $27 Million for Nonprofits 
Applied Materials Forecasts Strong Q3 Revenue as AI Chip Demand Accelerates 
DOJ May Drop Gautam Adani Fraud Charges Amid $10 Billion U.S. Investment Plan 
FTC Antitrust Probe Targets Arm Holdings Over Chip Licensing Practices 
Alphabet Raises Record $3.6 Billion in Yen Bonds to Support AI Expansion 
US-China Trade Talks Sideline Chip Export Controls as Nvidia China Sales Draw Attention 
Samsung Union Talks Enter Final Stage as Strike Threat Looms 
SpaceX Shareholders Approve 5-for-1 Stock Split Ahead of Potential IPO 
Samsung Faces Major Strike Threat as Union Restarts Pay Talks 
SoftBank Shares Slide Despite Record Q4 Profit Fueled by OpenAI Investment 
Samsung Strike Talks Resume as South Korea Weighs Emergency Action 
BlackRock-Led GCC Infrastructure Partnership Targets $30 Billion Investment 
Telefónica Q1 2026 Earnings Beat Expectations as Debt Declines and Cash Flow Improves 
Nvidia’s China AI Chip Sales Remain Frozen Despite U.S. Approval 
Elliott Targets Bio-Rad as Shares Continue to Struggle 
Sonova Beats Profit Forecasts Despite Cochlear Implant Weakness 
Anthropic Nears $30 Billion Funding Round at $900 Billion Valuation 
BERKELEY, Calif., Sept. 22, 2016 -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology in New York, NY on Thursday, September 29, 2016, at 8:00 am Eastern Time.
To access the live webcast and subsequent archived recording of this and the company’s other presentations, please visit Aduro's website at www.aduro.com.
About Aduro
Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. This platform is being developed as a treatment for multiple indications, including pancreatic, ovarian, lung and prostate cancers, mesothelioma and glioblastoma. Aduro's STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in a Phase 1 study in patients with cutaneously accessible metastatic solid tumors or lymphomas. Aduro’s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit www.aduro.com.
Contact: Alexandra Santos Sr. Director, Corporate Affairs 510 809 9231 Media Contact: Angela Bitting 925 202 6211 [email protected]
